Newsroom | Co-Diagnostics, Inc.

Newsroom

Month Year

Media Resources

Aug 3, 2020

Co-Diagnostics, Inc. Technology to be Used in FDA-Authorized Self-Collected COVID-19 Saliva Test

Salt Lake City, Utah – August 3, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX) (the Company), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests,
Jun 9, 2020

Co-Diagnostics, Inc. to Join Russell 2000® and Russell 3000® Indexes

Salt Lake City, Utah – June 9, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX) (the Company), a molecular diagnostics company with a unique, patented platform for the development of diagnostic...
May 27, 2020

Co-Diagnostics, Inc. to Present at COVID-19 Virtual Conference Hosted by Maxim Group on May 27, 2020

Salt Lake City, Utah – May 27, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX) (the Company), a molecular diagnostics company with a unique, patented platform for the development of diagnostic...
May 26, 2020

Co-Diagnostics, Inc. COVID-19 Test Successfully Used to Identify Coronavirus in Cancer Tissue

Tissue from presymptomatic patient in Italy was found to contain SARS-CoV-2 using Company’s Logix Smart™ COVID-19 test kit

Salt Lake City, Utah – May 26, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX) (the Company), a molecular diagnostics company with a unique, patented platform for the development of diagnostic...
May 14, 2020

Co-Diagnostics, Inc. Announces Q1 2020 Results and Provides Mid-Second Quarter Update

Company reports robust sales of COVID-19 tests as Co-Diagnostics generates net profit through middle of second quarter

Salt Lake City, Utah – May 14, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX) (the Company), a molecular diagnostics company with a unique, patented platform for the development of diagnostic...
May 14, 2020

Co-Diagnostics, Inc. Releases Prepared Remarks for First Quarter 2020 Conference Call

Salt Lake City, Utah – May 12, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX) (the Company), a molecular diagnostics company with a unique, patented platform for the development of diagnostic...
May 12, 2020

Co-Diagnostics, Inc. Announces Q1 2020 Earnings Release Date and Earnings Call

Salt Lake City, Utah – May 12, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX) (the Company), a molecular diagnostics company with a unique, patented platform for the development of diagnostic...
May 4, 2020

Co-Diagnostics, Inc. Announces Government Approvals and Increased Orders for COVID-19 Test Kits

Salt Lake City, Utah – May 4, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX) (the Company), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests,...
May 1, 2020

Co-Diagnostics, Inc. Releases COVID-19 Test Performance Data: Consistently Demonstrates 100% Sensitivity and 100% Specificity Across Independent Evaluations

Salt Lake City, Utah – May 1, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX) (the Company), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests,...
Apr 20, 2020

Co-Diagnostics, Inc. Announces Expansion of COVID-19 Test Orders in the United States

Salt Lake City, Utah – April 20, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced...
Apr 16, 2020

Co-Diagnostics, Inc. COVID-19 Test Technology Validated for Use on Saliva Samples

Salt Lake City, Utah – April 16, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX) (the Company), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests,
Apr 14, 2020

Co-Diagnostics, Inc Contracts with Promega Corp for COVID-19 Test Manufacturing as Company Expands Domestic Customer Base

Salt Lake City, Utah – April 14, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX) (the Company), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests,
Apr 6, 2020

Co-Diagnostics, Inc Receives FDA Emergency Use Authorization for COVID-19 Test

Salt Lake City, Utah – April 6, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced...
Mar 31, 2020

Co-Diagnostics, Inc. Reports 2019 Year-End Financial Results and Progress Updates

Salt Lake City, Utah – March 31, 2020 – Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests,...
Mar 20, 2020

Co-Diagnostics, Inc Completes Successful Clinical Evaluation Required for FDA Emergency Use Authorization

Company accelerates U.S. sales of COVID-19 test pursuant to new FDA policy

Salt Lake City, Utah – March 19, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced...
Mar 19, 2020

Co-Diagnostics JV CoSara First Indian Company to Receive License for COVID-19 Diagnostic

Salt Lake City, Utah – March 19, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced...
Mar 17, 2020

FDA Policy Change to Allow Rapid Domestic Expansion of Co-Diagnostics COVID-19 Test

Salt Lake City, Utah – March 17, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced...
Mar 12, 2020

Co-Diagnostics, Inc Chief Scientific Officer to Address Bipartisan Commission on Biodefense in Washington, D.C.

***UPDATE*** Due to travel restrictions and health concerns, the conference has been canceled. We will post any further updates here. Salt Lake City, Utah – March 12, 2020 – Co-Diagnostics,...
Mar 5, 2020

Co-Diagnostics, Inc. Reports Additional Demand for Coronavirus Test Shipments

Salt Lake City, Utah – March 5, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced...
Mar 3, 2020

Co-Diagnostics, Inc. Invited to Speak on Coronavirus at Molecular Med Tri-Con in San Francisco

Salt Lake City, Utah – March 2, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests and that...
Mar 2, 2020

Co-Diagnostics Announces Closing of $4.2 Million Registered Direct Offering Priced At-the-Market

Salt Lake City, Utah – March 02, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, today...
Feb 27, 2020

Co-Diagnostics Announces $4.2 Million Registered Direct Offering Priced At-the-Market

Salt Lake City, Utah – February 27, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, today...
Feb 24, 2020

Co-Diagnostics, Inc Receives CE Mark for Novel Coronavirus Test

Logix Smart™ COVID-19 Test now available for export from the United States as a CE-marked IVD

Salt Lake City, Utah – February 24, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests,...
Feb 20, 2020

Co-Diagnostics Completes Submission of CE Marking Registration for COVID-19 Coronavirus Test

Company’s new Logix Smart™ COVID-19 Test expected to be available with CE marking in February 2020

Salt Lake City, Utah – February 20, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests,...
Feb 19, 2020

Co-Diagnostics Announces New Vector Control Orders and Continued Progress Toward Regulatory Clearance for Coronavirus Test

Salt Lake City, Utah – February 19, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests,...

Show per page